Paris, February 6, 2009 – BioAlliance Pharma SA (Euronext Paris-BIO), the specialty
pharmaceutical company focused on the treatment of opportunistic infections in cancer and
HIV, announces the presentation of its results on a new quinoline family acting as HIV
integrase inhibitors at the 16th Conference on Retroviruses and Opportunistic Infections
(CROI), in Montreal, Canada (February 8 to 11, 2009).
The emergence of resistance mutations against available antiretroviral drugs brings out the
need to develop new therapeutic targets. HIV integrase inhibitors open up a new way as a
promising class of antiretroviral drugs. They act by blocking the action of the integrase, a
viral enzyme that inserts the viral genome into the DNA of the host cell preventing so the
formation of the provirus. The development of safe and efficient integrase inhibitors will allow
to propose new therapies targeting simultaneously the three key viral enzymes, and thus to
strongly reduce emerging acquired resistance.
The presented data show the activity of quinolines, a new HIV integrase inhibitor family.
Their peculiar mechanism of action permits them to keep their activity on viruses resisting to
the other antiretroviral drug classes and on viruses resisting to the integrase inhibitor
(Isentress®, raltogravir – Merck and Co) presently on the market.
The poster: “A New Quinoline Family of HIV-1 Integrase Inhibitors Acting on HIV-1 Mutants
Selected by Integrase Strand Transfer Inhibitors” will be on line on BioAlliance website on
February 8, 2009.
About the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
The Conference on Retroviruses and Opportunistic Infections is a scientifically focused meeting of the
world’s leading researchers working to understand, prevent, and treat HIV/AIDS and its complications.
The mission of the Retrovirus Conference is to provide a forum for basic scientists and clinicians to
present, discuss, and critique their investigations into the biology and epidemiology of human
retroviruses and the diseases they produce with the ultimate goal of transplanting laboratory and
clinical research into progress against the AIDS epidemic.
About BioAlliance Pharma
A privileged partner for hospital specialists, BioAlliance Pharma is a specialty biopharmaceutical
company, which develops and markets innovative products more especially in the fields of
opportunistic infections or chemotherapy complications. Our targeted approaches, in areas where
medical needs are insufficiently met, contribute to overcoming drug resistance and improving health
and quality of life for patients. BioAlliance Pharma’s ambition is to become a leading player in Europe
in these fields by aligning innovation with patients’ needs.